Aquestive Therapeutics, Inc. (AQST)

NASDAQ: AQST · IEX Real-Time Price · USD
4.260
+0.160 (3.90%)
At close: Mar 28, 2024, 4:00 PM
4.350
+0.090 (2.11%)
After-hours: Mar 28, 2024, 7:59 PM EDT
3.90%
Market Cap 368.87M
Revenue (ttm) 50.58M
Net Income (ttm) -7.87M
Shares Out 89.97M
EPS (ttm) -0.13
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 7,198,465
Open 4.260
Previous Close 4.100
Day's Range 4.220 - 4.480
52-Week Range 1.000 - 6.230
Beta 2.84
Analysts Strong Buy
Price Target 8.60 (+101.88%)
Earnings Date Mar 5, 2024

About AQST

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of... [Read more]

Sector Healthcare
IPO Date Jul 25, 2018
Employees 135
Stock Exchange NASDAQ
Ticker Symbol AQST
Full Company Profile

Financial Performance

In 2023, AQST's revenue was $50.58 million, an increase of 6.09% compared to the previous year's $47.68 million. Losses were -$7.87 million, -85.54% less than in 2022.

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for AQST stock is "Strong Buy." The 12-month stock price forecast is $8.6, which is an increase of 101.88% from the latest price.

Price Target
$8.6
(101.88% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Aquestive Therapeutics Announces Closing of Underwritten Public Offering of Common Stock

WARREN, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvemen...

3 days ago - GlobeNewsWire

Aquestive Therapeutics Announces Pricing of $75 Million Underwritten Public Offering of Common Stock

WARREN, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvemen...

9 days ago - GlobeNewsWire

Aquestive Therapeutics Announces Proposed Public Offering of Common Stock

WARREN, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (Nasdaq: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvemen...

9 days ago - GlobeNewsWire

Aquestive Therapeutics Announces Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Successfully Meets Primary and Secondary Endpoints and Provides Clinical Development Update Following FDA Meeting

WARREN, N.J., March 14, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through in...

14 days ago - GlobeNewsWire

Aquestive Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

WARREN, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through inn...

23 days ago - GlobeNewsWire

Aquestive Therapeutics to Report Fourth Quarter 2023 Financial Results and Recent Business Highlights on March 5 and Host Conference Call on March 6 at 8:00 a.m. ET

WARREN, N.J., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvement...

5 weeks ago - GlobeNewsWire

Aquestive Therapeutics to Present Anaphylm™ (epinephrine) Sublingual Film Pharmacokinetic and Pharmacodynamic Data at the 2024 AAAAI Annual Meeting

WARREN, N.J., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvement...

6 weeks ago - GlobeNewsWire

Aquestive Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Conference

WARREN, N.J., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through inn...

2 months ago - GlobeNewsWire

Aquestive Therapeutics Doses First Patient in Phase 3 Pivotal Clinical Study Evaluating Pharmacokinetics and Pharmacodynamics of Anaphylm™ (epinephrine) Sublingual Film

WARREN, N.J., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvement...

4 months ago - GlobeNewsWire

Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies for Anaphylm™ at American College of Allergy Asthma and Immunology (ACAAI) Annual Meeting

WARREN, N.J., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvement...

4 months ago - GlobeNewsWire

Aquestive Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

WARREN, N.J., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through inno...

5 months ago - GlobeNewsWire

Aquestive Therapeutics Completes $45 Million Debt Refinancing

WARREN, N.J., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through inno...

5 months ago - GlobeNewsWire

Aquestive Therapeutics Provides Business Update

WARREN, N.J., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and ...

6 months ago - GlobeNewsWire

Aquestive Therapeutics Reaffirms Timeline and Pathway for Anaphylm™ (epinephrine) Sublingual Film

WARREN, N.J., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and...

6 months ago - GlobeNewsWire

Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences

WARREN, N.J., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients' problems wit...

7 months ago - GlobeNewsWire

Aquestive Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

WARREN, N.J., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and ...

8 months ago - GlobeNewsWire

Aquestive Therapeutics to Participate in 2023 Wedbush PacGrow Healthcare Conference

WARREN, N.J., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients' problems wit...

8 months ago - GlobeNewsWire

Aquestive Therapeutics to Report Second Quarter 2023 Financial Results and Recent Business Highlights on August 7 and Host Conference Call on August 8 at 8:00 a.m. ET

WARREN, N.J., July 25, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients' problems wi...

8 months ago - GlobeNewsWire

Aquestive Therapeutics to Present Positive Topline Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm ™ (epinephrine) Sublingual Film at Aspen Allergy Conference

WARREN, N.J., July 25, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients' problems wit...

8 months ago - GlobeNewsWire

Aquestive Therapeutics Provides Business Update and Announces Chief Medical Officer Appointment

WARREN, N.J., June 29, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients' problems wit...

9 months ago - GlobeNewsWire

Aquestive Therapeutics Reports Positive Results from Latest Clinical Studies Evaluating Pharmacokinetic and Pharmacodynamic Performance of Anaphylm ™ (epinephrine) Sublingual Film and Provides Findings from Recent Auto-Injector Clinical Study

WARREN, N.J., May 31, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients' problems with...

10 months ago - GlobeNewsWire

Aquestive Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

WARREN, N.J., May 02, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and p...

11 months ago - GlobeNewsWire

Aquestive Therapeutics Expands License and Supply Agreement with Pharmanovia for Libervant™ (diazepam) Buccal Film to Additional Global Markets

WARREN, N.J., March 29, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and...

1 year ago - GlobeNewsWire

Aquestive Therapeutics Reports Fourth Quarter & Full Year 2022 Financial Results and Provides Business Update on Key 2023 Objectives

WARREN, N.J., March 07, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and...

1 year ago - GlobeNewsWire

Aquestive Therapeutics to Participate in Oppenheimer 33rd Annual Healthcare Conference

WARREN, N.J., March 01, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care an...

1 year ago - GlobeNewsWire